ArticlePloS one2026
Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocardial infarction (MI) induces cardiac remodeling and lead to heart failure. Some patients experience reverse remodeling, characterized by improved LV function. MicroRNAs (miRNAs) regulate gene expression and play a crucial role in remodeling processes.
objectivesWe aimed to investigate the role of miRNAs in cardiac reverse remodeling after MI and identify candidate miRNAs that could predict better response to cardiac rehabilitation.
methodsThe study enrolled 39 patients following their first MI. For final analysis, 10 patients meeting echocardiographic criteria for LVRR at 8-week follow-up (absolute LVEF increase ≥ 10% or LVESV reduction ≥ 15%) were matched with 10 patients with stable LV status (SLVS). All patients completed a cardiac rehabilitation program. Expression of 375 circulating miRNAs was quantified - those with higher baseline accumulation in the LVRR group were identified as candidate biomarkers and their target genes were analyzed.
resultsTwenty patients (mean age 57 ± 9 years) were analyzed. At baseline, the SLVS group exhibited significantly higher LVEF compared to the LVRR group (53% vs. 44%, p = 0.013). Baseline regional contractility impairment in all LVRR patients was reversed in 70% of them at follow-up. Fourteen miRNAs (-15b-5p, -24-3p, -29c-3p, -99b-5p, -127-3p, -146a-5p, -199a-3p, -361-5p, -502-5p, -625-5p, -376c-3p, -18b-5p, -342-5p, and -429) were identified as candidate LVRR biomarkers. Enrichment analysis linked their targets to PI3K-Akt, MAPK, FoxO, and HIF-1 pathways.
conclusionsThis study identifies 14 candidate miRNAs as LVRR biomarkers post-MI. These findings highlight the biological relevance of non-coding RNA and support the need for further research and validation in large, non-pooled cohorts. UNSTRUCTURED ABSTRACT: Myocardial infarction triggers adverse cardiac remodeling, though some patients achieve left ventricular reverse remodeling (LVRR), marked by functional and structural recovery. This pilot study investigated 39 patients to identify circulating microRNAs (miRNAs) that predict positive responses to cardiac rehabilitation. Comparing 10 LVRR responders against 10 stable patients, we quantified 375 miRNAs via RT-qPCR. At baseline, the stable group had higher ejection fractions (53% vs. 44%, p = 0.013), but 70% of LVRR patients reversed regional contractility impairment by the 8-week follow-up. We identified 14 potential biomarkers, including novel candidates (miR-502-5p, miR-376c-3p, and miR-18b-5p), whose target genes enrich pathways like PI3K-Akt, MAPK, and FoxO. These findings bridge the gap between preclinical data and clinical settings, highlighting the therapeutic potential of non-coding RNAs in cardiac reverse remodeling and necessitating further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.